Select publications

ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Blum JL et al. A Phase II trial of combination therapy with capecitabine (C) and weekly paclitaxel (P) for metastatic breast cancer (MBC): Preliminary results in taxane-naïve patients. Breast Cancer Res Treat 2004;88(Suppl 1);Abstract 5053.

Blum JL et al. ABI-007 nanoparticle paclitaxel: Demonstration of anti-tumor activity in taxanerefractory metastatic breast cancer. Presentation. ASCO, 2004;Abstract 543.

Blum JL et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17(2):485-93. Abstract

Gradishar WJ et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study. J Clin Oncol 2004;22(12):2321-7. Abstract

Ibrahim NK et al. Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer (MBC): Efficacy and evidence of dose-dependent activity in two multicenter phase II studies. Proc ASCO 2002;Abstract 209.

Ibrahim NK et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, proteinstabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8(5):1038-44. Abstract

Lee SH et al. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncol 2004;21(3):223-31. Abstract

Leonard R et al. Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda). Semin Oncol 2004;31(5 Suppl 10):21-8. Abstract

Mackey JR et al. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. Clin Breast Cancer 2004;5(4):287- 92. Abstract

Miles D et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: Analysis of therapy in a randomized phase III trial. Clin Breast Cancer 2004;5(4):273-8. Abstract

Nyman DW et al. A phase I trial of ABI-007, nanoparticle paclitaxel, administered to patients with advanced nonhematologic malignancies. J Clin Oncol 2004;22(14 Suppl);Abstract 2027.

O’Shaughnessy J et al. ABI-007 (ABRAXANE ), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs Taxol in MBC: A phase III trial. Breast Cancer Res Treat 2003;82(Suppl 1):3;Abstract 44.

O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract

O’Shaughnessy JA et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. Breast Cancer Res Treat 2004;88(Suppl 1);Abstract 1070.

Perez EA et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001;19(22):4216-23. Abstract

Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Huntingt) 2004;18(9):1161-8, 1173. Abstract

Seidman AD et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16(10):3353-6. Abstract